Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

BACKGROUND: Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no evidence for its ability to prolong overall surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Minjie, Zhou, Zhirui, Huang, Xiao, Chen, Zhenchao, Zhang, Licheng, Zhang, Jinsen, Hua, Wei, Mao, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265794/
https://www.ncbi.nlm.nih.gov/pubmed/37316802
http://dx.doi.org/10.1186/s12885-023-11043-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265794/
https://www.ncbi.nlm.nih.gov/pubmed/37316802
http://dx.doi.org/10.1186/s12885-023-11043-6

Ejemplares similares